# AbCellera Biologics (ABCL) investment thesis

By Clearthesis. Data as of July 1, 2026. Written July 1, 2026. Full page: https://www.clearthesis.ai/thesis/ABCL?utm_source=ai_agent&utm_medium=markdown

AbCellera Biologics uses an AI-driven technology platform to discover antibody-based drugs for the world's largest pharmaceutical companies.

The question investors are asking: AbCellera's stock has struggled to find a direction since its pandemic-era peaks. Can its massive portfolio of future drug royalties eventually turn it into a profitable giant, or will the long wait for results exhaust its cash?

## Summary

AbCellera is a technology-heavy biotech engine that generates rights to a massive portfolio of future drug royalties. The business will remain high-quality only if these discovery programs can successfully navigate the clinical trial process.

## The thesis in brief

- AbCellera Biologics is an antibody discovery engine that searches natural immune systems to find the starting points for new medicines. It generated $80 million in revenue last year and has already moved 19 different molecules into human clinical trials.
- The investment thesis on AbCellera Biologics is that it is building a high-margin royalty bank by trading its technology for a slice of future drug sales. It owns pieces of over 100 drug programs that can generate cash without the company paying for expensive human clinical trials.
- The main growth driver is the maturation of these partner programs as molecules move from the lab into late-stage human testing. A single successful medicine reaching the market could produce royalty payments that exceed the total revenue the company generates today.
- The biggest risk is that drug discovery is a high-stakes game where even the best technology cannot guarantee a medicine works. We view the stock as a watch for now because the most significant royalty payoffs are still several years away.

- AbCellera Biologics builds a portfolio of future drug royalties for other companies.
- It owns pieces of 100 drug programs without paying for human trials.
- The business has $533 million in cash and 19 molecules in clinical testing.
- We lean neutral: the technology is proven but the payoff remains years away.

## The business

- Stage: Growth

What does it do? AbCellera Biologics is a growth-stage biotech company that earns money by discovering new antibodies for pharmaceutical partners in exchange for milestone payments and future royalties. The company uses its AI-driven technology stack to search the immune systems of humans and animals for rare antibodies that can be turned into drugs. Instead of developing these drugs itself, which is expensive and risky, AbCellera performs the early discovery work and then hands the "recipe" to a partner like Eli Lilly or Regeneron. These partners handle the multi-year clinical trials and manufacturing, while AbCellera keeps a percentage of any eventual sales.

Where does revenue come from? The majority of current revenue comes from research fees and milestone payments, though the long-term goal is for royalties to dominate the mix. Research fees are paid upfront to use the platform, while milestones are bonuses triggered when a partner moves a drug into a new phase of human testing. Geographically, most revenue is generated through partnerships with major global pharmaceutical companies based in the United States and Europe.

Who are its customers? AbCellera serves a total of 104 partner-initiated programs with downstreams, ranging from the world's largest pharmaceutical giants to small, venture-backed biotech startups. As of the end of 2025, the company has successfully moved 19 molecules into clinical trials, providing a clear track record that its discovery engine produces viable drug candidates. The customer base is highly concentrated among professional drug developers who pay for access to AbCellera’s specialized technology to speed up their own internal research pipelines. This model allows AbCellera to diversify its risk across hundreds of different disease targets, from cancer to autoimmune conditions, without the burden of running its own clinical trials.

What gives it staying power? Its staying power comes from the sheer speed and depth of its discovery engine, which uses machine learning to screen millions of cells in days. This technical edge creates high switching costs, as partners who integrate AbCellera’s data into their research programs are unlikely to restart discovery elsewhere.

Where is it headed? The company is shifting toward "co-development," where it takes on more cost and risk in exchange for much larger ownership stakes in the drugs it discovers. Management is using its $533 million cash reserve to build internal manufacturing and laboratory facilities. This move is designed to capture more of the value chain and move the company beyond being just a service provider.

## Financial performance

Revenue is beginning to stabilize at around $80 million annually as the company works through the post-COVID trough. After a massive windfall from COVID-19 antibody royalties in 2021 and 2022, the business is now rebuilding its baseline through a diversified portfolio of non-COVID discovery programs.

Cash generation remains deeply negative, with a free cash flow burn of $170 million last year to fund aggressive lab and facility expansion. This divergence from earnings is intentional, as the company is investing heavily in property and equipment to support its new co-development strategy.

The balance sheet is exceptionally strong with $533 million in total cash and marketable securities and very little debt. This provides AbCellera with several years of runway to fund operations even without a major new royalty stream, serving as a critical safety net in a capital-intensive industry.

AbCellera is a financially resilient but currently loss-making business that is successfully transitioning away from its reliance on a single pandemic-era product.

- Last quarter note: In the most recent reported quarter, AbCellera generated $10 million in revenue and an EPS loss of $0.14. This result signals a steady but slow rebuilding of the business as partner programs advance through early research phases.

What's working well? The clinical pipeline is expanding, with 19 molecules now in human trials compared to 16 a year ago. This progress is the most direct evidence that the discovery engine is functioning and that partners are successfully moving these candidates toward potential commercialization.

What to watch? The annual cash burn rate is the most critical factor to track while the company waits for a new royalty stream. If the co-development strategy takes longer than expected to produce a winner, the company may eventually need to raise more capital or slow its expansion.

## Moat and competition

- Moat: Narrow
- Industry stage: Growth
- Industry growth estimate: ~12% annually
- Competitors: [Adimab. Private platform that is the most direct competitor in antibody discovery services], [Schrodinger. SDGR. Uses physics-based software to predict drug behavior for many of the same partners], [Eurofins. ERFSF. Large laboratory service provider offering broader but less specialized discovery tools], [Twist Bioscience. TWST. Provides synthetic DNA tools that compete for early-stage discovery budgets]
- Moat sources: [Brand & IP. present], [Switching Costs. partial], [Network Effects. absent]
- Moat evidence: [Gross margin: 79%], [Molecules in clinic: 19], [Cumulative programs: 104]

### Industry
The antibody discovery market is a subset of the $200 billion biopharma R&D market, growing at double digits as drugs shift from simple chemicals to complex biologics. The industry is shaped by the structural reality that drug discovery is becoming harder and more expensive, forcing pharma companies to outsource the most technical parts of research. AbCellera stands as a high-end platform player in this market, positioned to benefit as biologics continue to take share from traditional pills over the next decade.

### Competition
The competitive dynamic is centered on technical precision and speed rather than price. Barriers to entry are high because of the massive data and specialized hardware needed to screen immune systems at scale, which protects established players from new entrants.

Adimab is the most dangerous threat, as it has a similar long-standing reputation for antibody discovery and already has dozens of drugs in the clinic. Schrodinger competes for the same R&D dollars by using software to simulate drug interactions, offering a different technical path to the same goal. The primary threat is the risk of a "commodity trap" if newer AI models make basic antibody discovery significantly cheaper for everyone.

AbCellera is currently holding its ground by expanding its cumulative program count and clinical pipeline. The company added eight new partner-initiated programs last year, proving that its platform remains in high demand despite rising competition.

### Moat
The primary protection is its intellectual property, specifically the combination of microfluidics and machine learning that allows it to find "needle in a haystack" antibodies. This technology acts as a narrow moat because it is difficult to replicate the proprietary data models the company has built over a decade of searches.

The 79% gross margins and the steady expansion of molecules in clinical trials prove the business model has fundamental value. However, the lack of recurring revenue outside of lumpy milestones means the moat is not yet wide enough to protect against a prolonged dry spell in drug approvals.

The moat is currently stable, and the single most important signal will be whether the first wave of non-COVID molecules can reach the late-stage trials required for significant royalty payments. The platform works in the lab, but its true strength is still being tested in the clinic.

## Management

- CEO: Carl Hansen
- Management rating: Strong
- Execution: Mixed
- Execution evidence: Scaled to 19 clinical molecules but revenue remains lumpy post-COVID.
- Capital allocation: Disciplined
- Capital allocation evidence: Retained $533M in cash while building large-scale discovery infrastructure.
- Alignment: High
- Alignment evidence: Founder Carl Hansen maintains a large personal stake and leads the company's vision.
- Management decision: Investing in internal manufacturing and laboratory facilities to enable co-development
- Management decision: Successfully navigated the COVID-19 pandemic to deliver the first antibody treatment authorized by the FDA
- Management decision: Strategically shifted focus toward higher-value royalty-bearing programs over pure service fees

Carl Hansen is a founder-CEO who has demonstrated exceptional technical vision and the ability to attract top-tier global pharmaceutical partners. Unlike many biotech leaders who over-promote unproven science, Hansen has prioritized building a massive cash buffer and tangible infrastructure, which gives the company the strategic independence to survive long development cycles. His judgment was validated by the speed at which the company delivered its COVID-19 treatment, a feat of engineering that proved the platform can perform under extreme pressure.

The primary governance risk is that the company’s future is deeply tied to the strategic vision of its founder, with a board that is closely aligned with management. While the technical bench is deep, a departure of Hansen would likely trigger significant volatility in the strategy to move toward co-development. However, the high insider ownership and the absence of value-destructive acquisitions suggest that management is treating shareholder capital with the same caution they would their own.

## Quality scorecard

Each business is scored 1 to 5 on what makes a company worth owning for the long term.

- Moat strength: 3 out of 5. Proprietary AI and microfluidics stack provides a clear technical edge but faces intense competition.
- Capital efficiency: 2 out of 5. Currently burning significant cash to build infrastructure, with ROIC currently deep in negative territory.
- Revenue growth: 4 out of 5. Revenue grew from $30M to $80M in 2025 as the non-COVID portfolio began to scale.
- Growth runway: 5 out of 5. The 104 current programs represent a tiny fraction of the global drug development market.
- Management: 4 out of 5. Founder-led team has built a massive cash buffer and delivered a successful COVID drug.
- AI resilience: 5 out of 5. Core discovery platform is fundamentally enhanced by AI, making it a beneficiary of machine learning.
- Risk resilience: 3 out of 5. Proved clinical speed during COVID-19, but the broader portfolio is still untested in late trials.

## Key numbers (as of July 1, 2026)

- Revenue over the last twelve months: $0.1 billion
- Revenue growth from a year earlier: 160.6%
- Average yearly revenue growth over five years: -33.1%
- Gross margin: 79.1%
- Operating margin: -289.0%
- Free cash flow margin: -238.9%
- Return on invested capital: -13.6%

## Fair value and verdict

Clearthesis also estimates AbCellera Biologics's fair value, models what the stock could be worth over the next five years, and gives a verdict (whether it looks like a buy at today's price). Those are on the full thesis: https://www.clearthesis.ai/thesis/ABCL?utm_source=ai_agent&utm_medium=markdown

Latest news and what it means for the thesis: https://www.clearthesis.ai/updates/ABCL?utm_source=ai_agent&utm_medium=markdown

## Sources

- [SEC 10-K Annual Report](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=ABCL&type=10-K&dateb=&owner=include&count=5), July 1, 2026
- [SEC 10-Q Quarterly Report](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=ABCL&type=10-Q&dateb=&owner=include&count=5), July 1, 2026
- [AbCellera Reports Full Year 2025 Business Results](https://investors.abcellera.com/news/news-releases/2026/AbCellera-Reports-Full-Year-2025-Business-Results/default.aspx), July 1, 2026
- [AbCellera Reports Q1 2026 Business Results & Announces Positive ...](https://investors.abcellera.com/news/news-releases/2026/AbCellera-Reports-Q1-2026-Business-Results--Announces-Positive-Interim-Phase-1-Clinical-Data-for-ABCL635/default.aspx), July 1, 2026
- [AbCellera to Report Full Year 2025 Financial Results on February ...](https://investors.abcellera.com/news/news-releases/2026/AbCellera-to-Report-Full-Year-2025-Financial-Results-on-February-24-2026/default.aspx), July 1, 2026
- [AbCellera Biologics Inc. - AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call](https://investors.abcellera.com/news/news-releases/2026/AbCellera-to-Highlight-Phase-1-Clinical-Data-for-ABCL635-During-Upcoming-First-Quarter-2026-Earnings-Call/default.aspx), July 1, 2026
- [Earnings Press Release (2025-04-21)](https://www.sec.gov/Archives/edgar/data/1689731/000162828025018773/a1q25earningsrelease.htm), April 22, 2025
- [10-K (2024-12-31)](https://www.sec.gov/Archives/edgar/data/1689731/000162828025012878/0001628280-25-012878-index.htm), March 14, 2025

Clearthesis research is for information and education only. It is not investment advice.
